Charming Medical
MCTA
29.36
0.00
0.00%
Charming Medical
US · MCTA
#3746 by market cap
Listed 2025
29.36
0.00
0.00%
Live - 5344 symbols - heartbeat 254s ago
· 2026-10-07 19:54
- Market cap
- 504.26M
- P/E (TTM)i
- -29,355.00
- P/Bi
- 97.20
- EPSi
- 0.00
- Div yieldi
- 0.00%
- 52W posi
- 91%
Reader sentiment
Are you bullish or bearish on MCTA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 65.55, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 4 years
Latest year -22.73% YoY
Margins
- Gross margin
- 62.58%
- Operating margin
- 2.68%
- Net margin
- -0.47%
Key ratios & quality
- Altman Z-Scorei
- 65.55
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Revenue | 3.53M | 6.02M | 6.22M | 4.81M |
| Gross profit | 1.49M | 3.91M | 4.18M | 3.01M |
| Selling & admin expenses | 1.66M | 2.35M | 2.32M | 2.68M |
| Research & development | -- | -- | -- | -- |
| Operating profit | -287.50K | 1.17M | 1.62M | 128.87K |
| Pretax profit | -420.47K | 1.00M | 1.44M | 133.47K |
| Tax | -84.86K | 181.75K | 236.08K | 156.11K |
| Net profit | -335.61K | 821.74K | 1.20M | -22.65K |
| Basic EPS | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.02 | 0.05 | 0.07 | 0.00 |
| Line item | 2024-03 | 2024-09 | 2025-03 | 2025-09 | 2026-03 |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- |
| Selling & admin expenses | -- | -- | -- | -- | -- |
| Research & development | -- | -- | -- | -- | -- |
| Operating profit | -- | -- | -- | -- | -- |
| Pretax profit | -- | -- | -- | -- | -- |
| Tax | -- | -- | -- | -- | -- |
| Net profit | -- | -- | -- | -- | -- |
| Basic EPS | -- | -- | -- | -- | -- |
| Diluted EPS | -- | -- | -- | -- | -- |
Balance sheet
| Line item | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total current assets | 4.12M | 3.67M | 3.37M | 8.17M |
| Cash & ST investments | 1.93M | 2.10M | 2.76M | 6.54M |
| Inventory | 66.33K | 28.15K | 26.80K | 25.62K |
| Total assets | 6.38M | 4.88M | 5.36M | 9.87M |
| Total current liabilities | 7.17M | 5.88M | 4.95M | 4.33M |
| Short-term debt | 1.33M | 813.13K | 802.61K | 552.46K |
| Long-term debt | -- | -- | -- | -- |
| Total liabilities | 7,653,061.00 | 6,027,938.00 | 5,306,498.00 | 4,687,705.00 |
| Total equity | -1.27M | -1.15M | 49.24K | 5.18M |
| Retained earnings | -1.16M | -1.08M | 119.44K | 96.79K |
| Line item | 2024-03 | 2024-09 | 2025-03 | 2025-09 | 2026-03 |
|---|---|---|---|---|---|
| Total current assets | 3.67M | 3.31M | 3.37M | 2.93M | 8.17M |
| Cash & ST investments | 2.10M | 2.69M | 2.76M | 2.69M | 6.54M |
| Inventory | 28.15K | 34.15K | 26.80K | 39.98K | 25.62K |
| Total assets | 4.88M | 5.37M | 5.36M | 5.45M | 9.87M |
| Total current liabilities | 5.88M | 5.60M | 4.95M | 4.99M | 4.33M |
| Short-term debt | 813.13K | 895.10K | 802.61K | 467.08K | 552.46K |
| Long-term debt | -- | -- | -- | -- | -- |
| Total liabilities | 6,027,938.00 | 6,055,691.00 | 5,306,498.00 | 5,097,007.00 | 4,687,705.00 |
| Total equity | -1.15M | -681.06K | 49.24K | 357.97K | 5.18M |
| Retained earnings | -1.08M | -610.83K | 119.44K | 46.46K | 96.79K |
Cash flow
| Line item | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Operating cash flow | 2.43M | 295.43K | 425.89K | -1.22M |
| Depreciation & amortization | 211.08K | 391.70K | 263.45K | 216.07K |
| Free cash flow | 1.83M | 84.83K | 138.36K | -1.56M |
| Dividends paid | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- |
| Ending cash balance | 1.93M | 2.10M | 816.77K | 4.70M |
| Line item | 2024-03 | 2024-09 | 2025-03 | 2025-09 | 2026-03 |
|---|---|---|---|---|---|
| Operating cash flow | -- | -- | -- | -- | -- |
| Depreciation & amortization | -- | -- | -- | -- | -- |
| Free cash flow | -- | -- | -- | -- | -- |
| Dividends paid | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- |
| Ending cash balance | -- | -- | -- | -- | -- |
Returns & efficiency
| Line item | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| ROE %i | -- | -- | -- | -0.87 |
| ROA %i | -4.78 | 13.81 | 23.43 | -0.30 |
| ROIC %i | -- | -- | -- | -1.92 |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | -11.33 | 17.12 | 23.40 | 3.10 |
| FCF / sales %i | 51.76 | 1.41 | 2.22 | -- |
| Current ratioi | 0.57 | 0.62 | 0.68 | 1.89 |
| Quick ratioi | 0.57 | 0.62 | 0.68 | 1.88 |
| Debt / assetsi | 28.34 | 19.69 | 21.67 | 9.20 |
| LT debt / equityi | -- | -- | 727.07 | 6.86 |
| Interest coveragei | -19.75 | 39.52 | 69.75 | 9.45 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 10.84 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
| Line item | 2024-03 | 2024-09 | 2025-03 | 2025-09 | 2026-03 |
|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -0.87 |
| ROA %i | 13.81 | 16.23 | 23.43 | 12.14 | -0.30 |
| ROIC %i | -- | -- | -- | -- | -1.92 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- |
| EBIT margin %i | 17.12 | 18.02 | 23.40 | 15.78 | 3.10 |
| FCF / sales %i | 1.41 | 0.16 | 2.22 | 7.40 | -- |
| Current ratioi | 0.62 | 0.59 | 0.68 | 0.59 | 1.89 |
| Quick ratioi | 0.62 | 0.59 | 0.68 | 0.58 | 1.88 |
| Debt / assetsi | 19.69 | 25.21 | 21.67 | 10.51 | 9.20 |
| LT debt / equityi | -- | -- | 727.07 | 29.69 | 6.86 |
| Interest coveragei | 39.52 | 48.44 | 69.75 | 41.62 | 9.45 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Single segment100.00%
Region
Hong Kong100.00%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.